According to our prior observations that the PLK1/BACH1 axis contributes to the Vemurafenib resistance in melanoma, we investigated whether the PLK1 inhibitor Volasertib, in combination with Vemurafenib, could achieve improved therapeutic efficacy in melanoma. Here, BACH1 is linked to melanoma.